BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Wednesday presented promising preclinical data on BBO-11818, a drug developed for the treatment of KRAS-mutant cancers, at the 2026 annual meeting of the American Association for Cancer Research (AACR).
BBO-11818 is a selective, orally bioavailable, non-covalent inhibitor that targets mutant KRAS in both the ON (active GTP-bound) and OFF (non-active GDP-bound) states.
In preclinical testing, BBO-11818 showed inhibition of ERK phosphorylation and proliferation in KRAS-dependent cell lines in vitro. The drug was effective when combined in vivo with BBO-10203 and Cetuximab in KRAS-mutant CDX and PDX models. Additionally, BBO-11818 in combination with anti-PD-1 treatment showed strong tumor regression and the induction of an adaptive immune response.
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial.
BBOT has traded between $8.08 and $14.87 over the past year. The stock closed Wednesday's trading at $8.87, down 6.24%. In premarket trading, the stock is trading at $8.57, down 3.38%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.